AI Article Synopsis
- Ewing's sarcoma (ES) is a highly aggressive cancer primarily affecting teenagers, requiring a combination of surgery and systemic therapies for treatment.
- Many patients with ES develop drug resistance, which complicates their treatment and often leads to worsening disease.
- Recent research highlights the potential of targeting specific oncogenic drivers related to ES, providing new avenues for therapy and improving outcomes for patients.
Article Abstract
Ewing's sarcoma (ES) is an aggressive malignant tumor commonly affecting adolescents. The standard of care includes surgical treatment and systemic therapies, although ES patients often develop drug resistance, leading to disease progression. Tumorigenesis in Ewing's sarcoma has unique characteristics that allow for the development of targeted therapeutics. New data on the role of oncogenic drivers in ES tumorigenesis, particularly in relation to treatment-induced stress, offers new therapeutic opportunities. This review summarizes the latest information on the clinically relevant oncogenes found in Ewing's sarcoma, their biological roles, and candidate targets for improving ES patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287185 | PMC |
| http://dx.doi.org/10.1016/j.jbo.2022.100440 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!